Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies
Sponsor: Hospital de Clinicas de Porto Alegre
Summary
The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding. Researchers will compare desmopressin (DDAVP) to placebo to see if the drug reduces the risk of bleeding events related to kidney biopsy. Participants will receive intravenous desmopressin medication (100ml) or placebo (100mL of saline solution) before the kidney biopsy.
Official title: Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies: a Double-blind Randomized Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2024-08-14
Completion Date
2026-06-14
Last Updated
2025-09-11
Healthy Volunteers
No
Interventions
Desmopressin (DDAVP)
Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
Sodium Chloride
Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
Locations (1)
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil